行情

ACAD

ACAD

阿卡迪亚
NASDAQ

实时行情|Nasdaq Last Sale

39.91
+0.05
+0.13%
盘后: 40.50 +0.59 +1.48% 18:45 08/13 EDT
开盘
39.63
昨收
39.86
最高
41.14
最低
39.51
成交量
208.39万
成交额
--
52周最高
58.72
52周最低
23.77
市值
62.93亿
市盈率(TTM)
-27.2126
分时
5日
1月
3月
1年
5年

分析师评级

16位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ACAD价格均价为59.13,最高价位71.00,最低价为42.00。

EPS

ACAD 新闻

更多
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
Zacks · 08/06 17:19
ACADIA Pharma EPS beats by $0.18, beats on revenue
ACADIA Pharma (NASDAQ:ACAD): Q2 GAAP EPS of -$0.27 beats by $0.18. Revenue of $110.1M (+32.3% Y/Y) beats by $6.69M. Shares +4%. Press Release
seekingalpha · 08/06 01:07
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 22:25
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the s
Business Wire · 08/05 20:05
ACADIA Pharma Q2 2020 Earnings Preview
ACADIA Pharma (NASDAQ:ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 5th, after market close. The consensus EPS Estimate is -$0.43
seekingalpha · 08/05 02:35
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)
San Diego, California--(Newsfile Corp. - July 31, 2020) - If you would like to discuss your legal rights email leo@barrlaw.com or call (619) 780-3993. ACADIA Pharmaceuticals (ACAD) Accused of Misleading Shareholders. Securities Class Action Survives Motion to
Newsfile · 08/01 00:00
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of dementia-related psychosis on more than 200 patients to bet
Business Wire · 07/29 13:00

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

ACAD 简况

ACADIA Pharmaceuticals Inc.是一家生物医药公司。该公司专注于开发用于治疗中枢神经系统疾病的药品,并将其商业化。该公司正处于研究阶段的主要候选药品NUPLAZID(Pimavanserin)用于治疗帕金森病精神错乱(PDP)。NUPLAZID是靶向5-HT2A受体的高选择性5-羟色胺反向激动剂(SSIA)。该公司的Pimavanserin是已完成第III阶段开发的化学药物,用于治疗PDP。NUPLAZID优先靶向5-HT2A受体。5-HT2A受体是一种在精神错乱中起主要作用的5-羟色胺受体。通过此机制,NUPLAZID已在第III试验阶段经验证可以有效治疗PDP,并可以避免现有抗精神病药物的副作用。
展开

微牛提供ACADIA Pharmaceuticals Inc.(NASDAQ-ACAD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ACAD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ACAD股票基本功能。